The price of Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares last traded on Wall Street rose 2.18% to $0.29.
DNA stock price is now -43.83% away from the 50-day moving average and -74.59% away from the 200-day moving average. The market capitalization of the company currently stands at $604.26M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
, while ‘Raymond James’ rates the stock as ‘Mkt Perform’
In other news, Dmytruk Mark E., insider sold 49,162 shares of the company’s stock on Jul 02 ’24. The stock was sold for $16,027 at an average price of $0.33. Upon completion of the transaction, the insider now directly owns 1,043,626 shares in the company, valued at $0.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 02 ’24, Coen Steven P. sold 13,520 shares of the business’s stock. A total of $4,408 was realized by selling the stock at an average price of $0.33. This leaves the insider owning 195,058 shares of the company worth $56566.82. A total of 32.78% of the company’s stock is owned by insiders.
During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $0.26 and a high of $2.54. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 5.34, and a quick ratio of 5.34. The fifty day moving average price for DNA is $0.49724 and a two-hundred day moving average price translates $1.11935 for the stock.
The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for 2024-03-31. The net profit margin was -409.12% and return on equity was -65.81% for DNA. The company reported revenue of $37.94 million for the quarter, compared to $80.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -52.98 percent.
